Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced the appointment of Gregory D. Perry as Chief Financial and Business Officer, Daniel S. Lynch as Chairman of the company's board of directors and Jane Pritchett Henderson as a member of the board of directors.
"Greg, Dan and Jane bring a wealth of management and financial leadership experience and are excellent additions to the Eleven team," said Abbie Celniker, PhD, President and Chief Executive Officer of Eleven Therapeutics. "Greg has a well-established track record in the biotechnology industry, including public and private companies, with experience in financings, strategic transactions, operations management, business planning and investor relations. At the board level, Dan's depth of industry expertise, including a history of building biotechnology and pharmaceutical companies, and Jane's direct business experience in the ocular field will serve us well as we move forward."
Prior to joining Eleven Biotherapeutics, Gregory D. Perry served as Interim Chief Financial Officer of InVivo Therapeutics (NVIV), the Company noted in a release. Prior to InVivo, Eleven said that Perry was Executive Vice President and Chief Financial Officer of Immunogen, Inc. (IMGN) from 2009 to 2013, where he led the company's strategic transition from a platform technology company to a product development company. Prior to Immunogen, Perry served as Chief Financial Officer (CFO) of Elixir Pharmaceuticals. He served as CFO of Domantis, Ltd. until its acquisition by GlaxoSmithKline in 2006, and as CFO of Transkaryotic Therapies, Inc. (TKT) until its acquisition by Shire plc in 2005. Before joining Transkaryotic Therapies in 2003, Perry served in financial management positions of increasing responsibility at PerkinElmer, Inc., Honeywell and GE's European medical systems business unit.
Daniel S. Lynch spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, including securing FDA approval of ERBITUX (Cetuximab), an important new cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December, 2010, when it was acquired by McKesson. More recently Dan was Executive Chairman of the board for Avila Therapeutics and Stromedix. In addition to Eleven Biotherapeutics, Dan is currently a member of the board of directors for BIND Therapeutics, bluebird bio, Blueprint Medicines, Nimbus Discovery and RaNA Therapeutics. Dan received his BA in Mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Jane Pritchett Henderson is Senior Vice President and Chief Business Officer at Kolltan Pharmaceuticals. Prior to joining Kolltan, Eleven said that she served as Vice President, Business Development at ISTA Pharmaceuticals, Inc., where she managed the process that culminated in the acquisition of ISTA by Bausch + Lomb. She also oversaw the identification and evaluation of acquisitions and licensing opportunities and intellectual property strategy at ISTA. Previously, Henderson was Executive Vice President, Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals and served in similar roles at Axerion Therapeutics. Prior to these corporate positions, Henderson held senior investment banking positions for close to two decades in the health care groups of HSBC Securities, CIBC World Markets, Lehman Brothers and Salomon Brothers. Henderson received her B.S. degree in Psychology from Duke University.
Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP- Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye.
((Comments on this story may be sent to firstname.lastname@example.org))